| 臺大學術典藏 |
2022-09-15T01:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:54Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-07T07:41:17Z |
Copy number alterations of depressed colorectal neoplasm predict the survival and response to oxaliplatin in proximal colon cancer
|
Chang L.-C.; HAN-MO CHIU; Ho B.-C.; Chen M.-H.; Hsu Y.-C.; Chiu W.-T.; Su K.-Y.; Shun C.-T.; Liang J.-T.; Yu S.-L.; Wu M.-S. |
| 臺大學術典藏 |
2022-09-07T06:39:14Z |
Metabolomics Investigation of Voriconazole-Induced Hepatotoxicity in Mice
|
Wu S.-L.; Wei T.-Y.; SHU-WEN LIN; Su K.-Y.; Kuo C.-H. |
| 臺大學術典藏 |
2022-08-10T02:37:41Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; Yu C.-J.; CHIH-HSIN YANG; Shih J.-Y. |
| 臺大學術典藏 |
2022-06-27T07:07:31Z |
Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations
|
Yuan S.; Yu S.-L.; Chen H.-Y.; Hsu Y.-C.; Su K.-Y.; Chen H.-W.; Chen C.-Y.; CHONG-JEN YU; Shih J.-Y.; Chang Y.-L.; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:02:08Z |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
|
Tsai T.-H.; Su K.-Y.; Wu S.-G.; Chang Y.-L.; Luo S.-C.; Jane I.-S.; CHONG-JEN YU; Yue S.-L.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:47Z |
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemona?ve patients with EGFR-mutant lung adenocarcinoma
|
Tseng J.-S.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; CHONG-JEN YU; Liao W.-Y.; Tsai C.-R.; Tsai M.-H.; Yu S.-L.; Su K.-Y.; Chen J.J.W.; Chen H.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:39Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; CHONG-JEN YU; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:36Z |
R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability
|
Chen H.-Y.; Yu S.-L.; Ho B.-C.; Su K.-Y.; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU; Chen K.-Y.; Tsai Y.-H.; Su W.-C.; Chen H.-W.; Chen J.J.W.; Chen C.-J.; Chang G.-C.; Yang P.-C.; Li K.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:29Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; CHONG-JEN YU; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:22Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; Yu K.-L.; Ho C.-C.; Shih J.-Y.; CHONG-JEN YU; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:17Z |
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
|
Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; Yu S.-L.; Su K.-Y.; CHONG-JEN YU; Ho C.C.; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Yang P.-C.; Chen J.J.W.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:13Z |
Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS
|
Su K.-Y.; Yan B.-S.; Chiu H.-C.; CHONG-JEN YU; Chang S.-Y.; Jou R.; Liu J.-L.; Hsueh P.-R.; Yu S.-L. |
| 臺大學術典藏 |
2022-06-27T07:00:13Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; CHONG-JEN YU; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:05Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T07:00:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; CHONG-JEN YU; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-06-27T06:59:47Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T06:59:43Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T06:59:37Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; CHONG-JEN YU; Chih-Hsin Yang J.; Shih J.-Y. |
| 臺大學術典藏 |
2022-05-03T04:01:35Z |
Transthyretin as a biomarker to predict and monitor major depressive disorder identified by whole?genome transcriptomic analysis in mouse models
|
Yu S.-L.; Chu S.S.-T.; Chien M.-H.; PO-HSIU KUO; Yang P.-C.; Su K.-Y. |
| 臺大學術典藏 |
2022-03-31T09:03:57Z |
Perinatal polychlorinated biphenyls and polychlorinated dibenzofurans exposure are associated with DNA methylation changes lasting to early adulthood: Findings from Yucheng second generation
|
Su K.-Y.; Li M.-C.; Lee N.-W.; Ho B.-C.; Cheng C.-L.; Chuang Y.-C.; Yu S.-L.; YUE-LIANG GUO |
| 臺大學術典藏 |
2022-03-09T03:12:33Z |
Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations
|
Yuan S.; Yu S.-L.; Chen H.-Y.; Hsu Y.-C.; Su K.-Y.; HUEI-WEN CHEN; Chen C.-Y.; Yu C.-J.; Shih J.-Y.; Chang Y.-L.; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; Yang P.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:26Z |
R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability
|
Chen H.-Y.; Yu S.-L.; Ho B.-C.; Su K.-Y.; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; Yu C.-J.; Chen K.-Y.; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN; Chen J.J.W.; Chen C.-J.; Chang G.-C.; Yang P.-C.; Li K.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:25Z |
Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients
|
Huang Y.-H.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Su K.-Y.; Chen H.-Y.; Chang C.-S.; Chen J.J.W.; Yu S.-L.; HUEI-WEN CHEN; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:24Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; HUEI-WEN CHEN; Yu S.-L.; Liu T.-W.; Chang G.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:22Z |
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment na?ve advanced EGFR-mutant lung adenocarcinoma patients
|
Hsu K.-H.; Huang Y.-H.; Tseng J.-S.; Chen K.-C.; Ku W.-H.; Su K.-Y.; Chen J.J.W.; HUEI-WEN CHEN; Yu S.-L.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:22Z |
The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma
|
Huang Y.-H.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Hsu C.-H.; Su K.-Y.; Chen J.J.W.; HUEI-WEN CHEN; Yu S.-L.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:18Z |
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression
|
Chen Y.-J.; Roumeliotis T.I.; Chang Y.-H.; Chen C.-T.; Han C.-L.; Lin M.-H.; HUEI-WEN CHEN; Chang G.-C.; Chang Y.-L.; Wu C.-T.; Lin M.-W.; Hsieh M.-S.; Wang Y.-T.; Chen Y.-R.; Jonassen I.; Ghavidel F.Z.; Lin Z.-S.; Lin K.-T.; Chen C.-W.; Sheu P.-Y.; Hung C.-T.; Huang K.-C.; Yang H.-C.; Lin P.-Y.; Yen T.-C.; Lin Y.-W.; Wang J.-H.; Raghav L.; Lin C.-Y.; Chen Y.-S.; Wu P.-S.; Lai C.-T.; Weng S.-H.; Su K.-Y.; Chang W.-H.; Tsai P.-Y.; Robles A.I.; Rodriguez H.; Hsiao Y.-J.; Chang W.-H.; Sung T.-Y.; Chen J.-S.; Yu S.-L.; Choudhary J.S.; Chen H.-Y.; Yang P.-C.; Chen Y.-J. |
| 臺大學術典藏 |
2022-03-04T05:33:28Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-03-04T05:33:27Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-03-04T05:33:27Z |
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression
|
Chen Y.-J.; Roumeliotis T.I.; Chang Y.-H.; Chen C.-T.; Han C.-L.; Lin M.-H.; Chen H.-W.; Chang G.-C.; Chang Y.-L.; CHEN-TU WU; Lin M.-W.; Hsieh M.-S.; Wang Y.-T.; Chen Y.-R.; Jonassen I.; Ghavidel F.Z.; Lin Z.-S.; Lin K.-T.; Chen C.-W.; Sheu P.-Y.; Hung C.-T.; Huang K.-C.; Yang H.-C.; Lin P.-Y.; Yen T.-C.; Lin Y.-W.; Wang J.-H.; Raghav L.; Lin C.-Y.; Chen Y.-S.; Wu P.-S.; Lai C.-T.; Weng S.-H.; Su K.-Y.; Chang W.-H.; Tsai P.-Y.; Robles A.I.; Rodriguez H.; Hsiao Y.-J.; Chang W.-H.; Sung T.-Y.; Chen J.-S.; Yu S.-L.; Choudhary J.S.; Chen H.-Y.; Yang P.-C.; Chen Y.-J. |
| 臺大學術典藏 |
2022-03-04T03:48:22Z |
Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice
|
Hsu Y.-C.; Huang H.-P.; Yu I.-S.; Su K.-Y.; Lin S.-R.; WEI-CHOU LIN; Wu H.-L.; Shi G.-Y.; Tao M.-H.; Kao C.-H.; Wu Y.-M.; Martin P.E.; Lin S.-Y.; Yang P.-C.; Lin S.-W. |
| 臺大學術典藏 |
2022-02-23T02:12:37Z |
Decreased expressions of hepsin in human hepatocellular carcinomas
|
CHIEN-HUNG CHEN; Su K.-Y.; Tao M.-H.; Lin S.-W.; Su Y.-H.; Tsai Y.-C.; Cheng K.-C.; Jeng Y.-M.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:31Z |
Decreased expressions of hepsin in human hepatocellular carcinomas
|
CHIEN-HUNG CHEN; Su K.-Y.; Tao M.-H.; Lin S.-W.; Su Y.-H.; Tsai Y.-C.; Cheng K.-C.; Jeng Y.-M.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-14T07:10:41Z |
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression
|
Chen Y.-J.; Roumeliotis T.I.; Chang Y.-H.; Chen C.-T.; Han C.-L.; Lin M.-H.; Chen H.-W.; Chang G.-C.; YIH-LEONG CHANG; Wu C.-T.; Lin M.-W.; Hsieh M.-S.; Wang Y.-T.; Chen Y.-R.; Jonassen I.; Ghavidel F.Z.; Lin Z.-S.; Lin K.-T.; Chen C.-W.; Sheu P.-Y.; Hung C.-T.; Huang K.-C.; Yang H.-C.; Lin P.-Y.; Yen T.-C.; Lin Y.-W.; Wang J.-H.; Raghav L.; Lin C.-Y.; Chen Y.-S.; Wu P.-S.; Lai C.-T.; Weng S.-H.; Su K.-Y.; Chang W.-H.; Tsai P.-Y.; Robles A.I.; Rodriguez H.; Hsiao Y.-J.; Chang W.-H.; Sung T.-Y.; Chen J.-S.; Yu S.-L.; Choudhary J.S.; Chen H.-Y.; Yang P.-C.; Chen Y.-J. |
| 臺大學術典藏 |
2022-02-14T07:10:40Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-01-20T07:58:02Z |
The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan
|
Lee C.-C.; Chang H.-H.; Lu M.-Y.; Yang Y.-L.; SHU-WEI CHOU; Lin D.-T.; Jou S.-T.; Yao M.; Li C.-C.; Yeh S.-P.; Chen M.-H.; Gau J.-P.; Li S.-S.; Wang P.-N.; Liu Y.-C.; Wang T.-F.; Tan T.-D.; Lee M.-Y.; Yu M.-S.; Wang C.-C.; Lin S.-C.; Chen Y.-C.; Su Y.-C.; Su K.-Y.; Lin K.-H. |
| 臺大學術典藏 |
2021-11-03T05:24:54Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; CHONG-JEN YU; Chih-Hsin Yang J.; Shih J.-Y. |
| 臺大學術典藏 |
2021-11-03T02:33:02Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; Yu C.-J.; Chih-Hsin Yang J.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2021-10-08T08:16:23Z |
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer
|
MONG-WEI LIN; Su K.-Y.; Su T.-J.; Chang C.-C.; Lin J.-W.; Lee Y.-H.; Yu S.-L.; Chen J.-S.; Hsieh M.-S. |
| 臺大學術典藏 |
2021-10-08T08:16:16Z |
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression
|
Chen Y.-J.; Roumeliotis T.I.; Chang Y.-H.; Chen C.-T.; Han C.-L.; Lin M.-H.; Chen H.-W.; Chang G.-C.; Chang Y.-L.; Wu C.-T.; MONG-WEI LIN; Hsieh M.-S.; Wang Y.-T.; Chen Y.-R.; Jonassen I.; Ghavidel F.Z.; Lin Z.-S.; Lin K.-T.; Chen C.-W.; Sheu P.-Y.; Hung C.-T.; Huang K.-C.; Yang H.-C.; Lin P.-Y.; Yen T.-C.; Lin Y.-W.; Wang J.-H.; Raghav L.; Lin C.-Y.; Chen Y.-S.; Wu P.-S.; Lai C.-T.; Weng S.-H.; Su K.-Y.; Chang W.-H.; Tsai P.-Y.; Robles A.I.; Rodriguez H.; Hsiao Y.-J.; Chang W.-H.; Sung T.-Y.; Chen J.-S.; Yu S.-L.; Choudhary J.S.; Chen H.-Y.; Yang P.-C.; Chen Y.-J. |
| 臺大學術典藏 |
2021-09-17T05:41:27Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2021-08-31T03:33:45Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
SHU-YUNG LIN; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-23T03:20:34Z |
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma
|
Tseng J.-S.; Wang C.-L.; Huang M.-S.; CHUNG-YU CHEN; Chang C.-Y.; Yang T.-Y.; Tsai C.-R.; Chen K.-C.; Hsu K.-H.; Tsai M.-H.; Yu S.-L.; Su K.-Y.; Wu C.-W.; Yang C.-T.; Chen Y.-M.; Chang G.-C. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
